- Global Pharma News & Resources

Cell and Gene Therapy CROs Market, 2018-2030 -

The "Cell and Gene Therapy CROs Market, 2018-2030" report has been added to's offering.

The Cell and Gene Therapy CROs Market, 2018-2030' report features a comprehensive study on the current landscape of contract research service providers in the cell and gene therapy sector. The study presents an in-depth analysis, highlighting the capabilities of stakeholders engaged in this domain, across different regions of the globe.

In the recent past, cell and gene therapies have emerged as promising treatment options for a myriad of complex clinical conditions, including cancers and inherited disorders. Currently, more than 25 such advanced therapy medicinal products are available in the market; examples of recently approved therapies include Alofisel (2018), LUXTURNA (2017), YESCARTA (2017), Kymriah (2017) and INVOSSA (2017). In addition, over 500 cell and gene therapy candidates are being investigated in different stages of clinical development, across various geographies.

In fact, in the past five years alone, more than 1,000 clinical trials that are currently active were initiated to evaluate the potential of these therapies across multiple therapeutic indications. Due to several development challenges, such as fragile nature of cells being used, safety and efficacy issues, laborious procedures for conducting clinical studies, complex regulatory framework and exorbitant costs, it is difficult for the companies with limited expertise and finances to successfully develop these therapies in-house. The aforementioned challenges have led several players to outsource a significant part of their clinical stage research to capable contract research organizations (CROs), which claim to offer cost-efficient solutions as well as intellectual and operational expertise.

In fact, various therapy developers have partnered with CROs to seek their support in advancing product candidates towards approval. Moreover, contract service providers have formed alliances to enhance their capabilities and provide an integrated suite of services. It is also worth highlighting that the industry has witnessed some consolidation in the last five years as smaller players have been acquired in an effort to widen the parent company's geographical reach.

One of the key objectives of this report is to evaluate the current opportunity and the future potential of the cell and gene therapy CROs market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long-term, for the period 2018-2030.

In addition, we have provided the likely distribution of the market based on [A] type of therapy (cell therapy and gene therapy) [B] scale of operation (clinical and preclinical), [C] type of therapeutic areas (oncology and non-oncology) and [D] geographical region regions (covering North America, Europe, Asia Pacific and rest of the world). To account for the uncertainties associated with the growth of cell and gene therapy CRO market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

Furthermore, service providers have invested in developing / adopting advanced tools, technologies and platforms in order to provide robust and evidence-based clinical data for approval. Given these technological advancements, the cost and time-related advantages of outsourcing research and the expanding pipeline of cell and gene therapy candidates, the demand for CROs is projected to grow in the foreseen future.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Guide To Outsourcing

5. Current Market Landscape

6. Company Profiles

7. Benchmark Analysis

8. Clinical Trial Analysis

9. Collaborations

10. Market Sizing And Opportunity Analysis

11. SWOT Analysis

12. Conclusion

13. Interview And Survey Transcripts

14. Appendix 1: Tabulated Data

15. Appendix 2: List Of Companies And Organizations

For more information about this report visit

View source version on

Editor Details

Last Updated: 05-Dec-2018